*Readmission Rate is calculated from Oct 2015 to Aug 2018 and all other Quality Outcomes are calculated from Oct 2015 to Sep 2018.
| T375X5A - Adverse effect of antiviral drugs, initial encounter - as a primary diagnosis code | T375X5A - Adverse effect of antiviral drugs, initial encounter - as a primary or secondary diagnosis code | |
|---|---|---|
| OUTCOMES | ||
| Avg. LOS | 6.95 | |
| Readmission Rate (%) | 23.8 | |
| Unplanned Readmission Rate (%) | NA | |
| Mortality Rate (%) | ||
| SNF Discharge Rate (%) | ||
| Home Discharge Rate (%) | ||
| PAYMENTS AND CHARGES | ||
| Total Medicare Payments | ||
| Payment Per Day | ||
| Payment Per Hospitalization | ||
| Total Medicare Charges | ||
| Avg. Charges | ||
| MARKET SIZING & INCIDENCE RATES | ||
| Total National Projected Hospitalizations - Annualized (Present on Admission - All) | ||
| Total Medicare Hospitalizations - Oct 2015 to Sep 2018 (Present on Admission - All) | ||
| Total National Projected Hospitalizations - Annualized (Present on Admission - Yes) | ||
| Total Medicare Hospitalizations - Oct 2015 to Sep 2018 (Present on Admission - Yes) | ||
| Total National Projected Hospitalizations - Annualized (Present on Admission - Not Y) | ||
| Total Medicare Hospitalizations - Oct 2015 to Sep 2018 (Present on Admission - Not Y) | ||
| Total Medicare Hospitalizations after Exclusion | ||
*Readmission Rate is calculated from Oct 2015 to Aug 2018 and all other Quality Outcomes are calculated from Oct 2015 to Sep 2018.
| DRG 917: POISONING AND TOXIC EFFECTS OF DRUGS WITH MAJOR COMPLICATION OR COMORBIDITY (MCC) | |
|---|---|
| Total Hospitalizations at DRG | 101,548 |
| Total Hospitalizations with ICD T375X5A - Adverse effect of antiviral drugs, initial encounter | 30 |
| DRG Share of Total Hospitalizations | 0.31 |
| % of Total ICD T375X5A - Adverse effect of antiviral drugs, initial encounter in DRG | 73.17 |
| Avg LOS at DRG | 4.68 |
| Avg LOS with ICD T375X5A - Adverse effect of antiviral drugs, initial encounter | 5.2 |
| Readmission Rate at DRG | 32.74 |
| Readmission Rate with ICD T375X5A - Adverse effect of antiviral drugs, initial encounter | NA |
| Unplanned Readmission Rate at DRG | 13.79 |
| Unplanned Readmission Rate with ICD T375X5A - Adverse effect of antiviral drugs, initial encounter | NA |
| Total Medicare payments at DRG | $922,969,291 |
| Total Medicare payments with ICD T375X5A - Adverse effect of antiviral drugs, initial encounter | $282,399 |
| Total Medicare payment per Day at DRG | $1,941 |
| Total Medicare payment per Day with ICD T375X5A - Adverse effect of antiviral drugs, initial encounter | $1,810 |
| Total Medicare payment per Hospitalization at DRG | $9,089 |
| Total Medicare payment per Hospitalization with ICD T375X5A - Adverse effect of antiviral drugs, initial encounter | $9,413 |
| Total Medicare Charges at DRG | $4,727,523,206 |
| Total Medicare Charges with ICD T375X5A - Adverse effect of antiviral drugs, initial encounter | $1,048,562 |
| Avg Charges at DRG | $46,555 |
| Avg Charges with ICD T375X5A - Adverse effect of antiviral drugs, initial encounter | $34,952 |
| Mortality Rate at DRG | 2.95 |
| Mortality Rate with ICD T375X5A - Adverse effect of antiviral drugs, initial encounter | NA |
| SNF Discharge Rate at DRG | 13.87 |
| SNF Discharge Rate with ICD T375X5A - Adverse effect of antiviral drugs, initial encounter | NA |
| Home Discharge Rate at DRG | 43.04 |
| Home Discharge Rate with ICD T375X5A - Adverse effect of antiviral drugs, initial encounter | 40.0 |
*Readmission Rate is calculated from Oct 2015 to Aug 2018 and all other Quality Outcomes are calculated from Oct 2015 to Sep 2018.
| DRG 091: OTHER DISORDERS OF NERVOUS SYSTEM WITH MAJOR COMPLICATION OR COMORBIDITY (MCC) | DRG 871: SEPTICEMIA OR SEVERE SEPSIS WITHOUT MV >96 HOURS WITH MAJOR COMPLICATION OR COMORBIDITY (MCC) | DRG 682: RENAL FAILURE WITH MAJOR COMPLICATION OR COMORBIDITY (MCC) | DRG 683: RENAL FAILURE WITH COMPLICATION OR COMORBIDITY (CC) | DRG 193: SIMPLE PNEUMONIA AND PLEURISY WITH MAJOR COMPLICATION OR COMORBIDITY (MCC) | |
|---|---|---|---|---|---|
| Total Hospitalizations at DRG | 101,617 | ||||
| Total Hospitalizations with ICD T375X5A - Adverse effect of antiviral drugs, initial encounter | 416 | ||||
| DRG Share of Total Hospitalizations | 0.31 | ||||
| % of Total ICD T375X5A - Adverse effect of antiviral drugs, initial encounter in DRG | 6.77 | ||||
| Avg LOS at DRG | 9.5 | ||||
| Avg LOS with ICD T375X5A - Adverse effect of antiviral drugs, initial encounter | 4.76 | ||||
| Readmission Rate at DRG | 26.88 | ||||
| Readmission Rate with ICD T375X5A - Adverse effect of antiviral drugs, initial encounter | 20.6 | ||||
| Unplanned Readmission Rate at DRG | 19.26 | ||||
| Unplanned Readmission Rate with ICD T375X5A - Adverse effect of antiviral drugs, initial encounter | 12.31 | ||||
| Total Medicare payments at DRG | $1,599,186,807 | ||||
| Total Medicare payments with ICD T375X5A - Adverse effect of antiviral drugs, initial encounter | $4,226,900 | ||||
| Total Medicare payment per Day at DRG | $1,656 | ||||
| Total Medicare payment per Day with ICD T375X5A - Adverse effect of antiviral drugs, initial encounter | $2,133 | ||||
| Total Medicare payment per Hospitalization at DRG | $15,737 | ||||
| Total Medicare payment per Hospitalization with ICD T375X5A - Adverse effect of antiviral drugs, initial encounter | $10,161 | ||||
| Total Medicare Charges at DRG | $4,836,538,333 | ||||
| Total Medicare Charges with ICD T375X5A - Adverse effect of antiviral drugs, initial encounter | $18,954,061 | ||||
| Avg Charges at DRG | $47,596 | ||||
| Avg Charges with ICD T375X5A - Adverse effect of antiviral drugs, initial encounter | $45,563 | ||||
| Mortality Rate at DRG | 2.8 | ||||
| Mortality Rate with ICD T375X5A - Adverse effect of antiviral drugs, initial encounter | NA | ||||
| SNF Discharge Rate at DRG | 20.21 | ||||
| SNF Discharge Rate with ICD T375X5A - Adverse effect of antiviral drugs, initial encounter | 20.19 | ||||
| Home Discharge Rate at DRG | 20.17 | ||||
| Home Discharge Rate with ICD T375X5A - Adverse effect of antiviral drugs, initial encounter | 44.47 |
*Readmission Rate is calculated from Oct 2015 to Aug 2018 and all other Quality Outcomes are calculated from Oct 2015 to Sep 2018.
| DRG 809: MAJOR HEMATOLOGICAL AND IMMUNOLOGICAL DIAGNOSES EXCEPT SICKLE CELL CRISIS AND COAGULATION DISORDERS WITH COMPLICATION OR COMORBIDITY (CC) | DRG 194: SIMPLE PNEUMONIA AND PLEURISY WITH COMPLICATION OR COMORBIDITY (CC) | DRG 392: ESOPHAGITIS, GASTROENTERITIS AND MISCELLANEOUS DIGESTIVE DISORDERS WITHOUT MAJOR COMPLICATION OR COMORBIDITY (MCC) | DRG 097: NON-BACTERIAL INFECTION OF NERVOUS SYSTEM EXCEPT VIRAL MENINGITIS WITH MAJOR COMPLICATION OR COMORBIDITY (MCC) | DRG 865: VIRAL ILLNESS WITH MAJOR COMPLICATION OR COMORBIDITY (MCC) | |
|---|---|---|---|---|---|
| Total Hospitalizations at DRG | 45,432 | ||||
| Total Hospitalizations with ICD T375X5A - Adverse effect of antiviral drugs, initial encounter | 148 | ||||
| DRG Share of Total Hospitalizations | 0.14 | ||||
| % of Total ICD T375X5A - Adverse effect of antiviral drugs, initial encounter in DRG | 2.41 | ||||
| Avg LOS at DRG | 4.42 | ||||
| Avg LOS with ICD T375X5A - Adverse effect of antiviral drugs, initial encounter | 4.55 | ||||
| Readmission Rate at DRG | 30.74 | ||||
| Readmission Rate with ICD T375X5A - Adverse effect of antiviral drugs, initial encounter | 24.09 | ||||
| Unplanned Readmission Rate at DRG | 18.94 | ||||
| Unplanned Readmission Rate with ICD T375X5A - Adverse effect of antiviral drugs, initial encounter | 10.95 | ||||
| Total Medicare payments at DRG | $376,347,273 | ||||
| Total Medicare payments with ICD T375X5A - Adverse effect of antiviral drugs, initial encounter | $1,276,442 | ||||
| Total Medicare payment per Day at DRG | $1,873 | ||||
| Total Medicare payment per Day with ICD T375X5A - Adverse effect of antiviral drugs, initial encounter | $1,894 | ||||
| Total Medicare payment per Hospitalization at DRG | $8,284 | ||||
| Total Medicare payment per Hospitalization with ICD T375X5A - Adverse effect of antiviral drugs, initial encounter | $8,625 | ||||
| Total Medicare Charges at DRG | $1,794,383,177 | ||||
| Total Medicare Charges with ICD T375X5A - Adverse effect of antiviral drugs, initial encounter | $6,901,946 | ||||
| Avg Charges at DRG | $39,496 | ||||
| Avg Charges with ICD T375X5A - Adverse effect of antiviral drugs, initial encounter | $46,635 | ||||
| Mortality Rate at DRG | 0.61 | ||||
| Mortality Rate with ICD T375X5A - Adverse effect of antiviral drugs, initial encounter | NA | ||||
| SNF Discharge Rate at DRG | 7.48 | ||||
| SNF Discharge Rate with ICD T375X5A - Adverse effect of antiviral drugs, initial encounter | NA | ||||
| Home Discharge Rate at DRG | 67.79 | ||||
| Home Discharge Rate with ICD T375X5A - Adverse effect of antiviral drugs, initial encounter | 73.65 |
*Readmission Rate is calculated from Oct 2015 to Aug 2018 and all other Quality Outcomes are calculated from Oct 2015 to Sep 2018.
| DRG 866: VIRAL ILLNESS WITHOUT MAJOR COMPLICATION OR COMORBIDITY (MCC) | DRG 974: HIV WITH MAJOR RELATED CONDITION WITH MAJOR COMPLICATION OR COMORBIDITY (MCC) | DRG 092: OTHER DISORDERS OF NERVOUS SYSTEM WITH COMPLICATION OR COMORBIDITY (CC) | DRG 947: SIGNS AND SYMPTOMS WITH MAJOR COMPLICATION OR COMORBIDITY (MCC) | DRG 438: DISORDERS OF PANCREAS EXCEPT MALIGNANCY WITH MAJOR COMPLICATION OR COMORBIDITY (MCC) | |
|---|---|---|---|---|---|
| Total Hospitalizations at DRG | 22,681 | ||||
| Total Hospitalizations with ICD T375X5A - Adverse effect of antiviral drugs, initial encounter | 103 | ||||
| DRG Share of Total Hospitalizations | 0.07 | ||||
| % of Total ICD T375X5A - Adverse effect of antiviral drugs, initial encounter in DRG | 1.68 | ||||
| Avg LOS at DRG | 3.32 | ||||
| Avg LOS with ICD T375X5A - Adverse effect of antiviral drugs, initial encounter | 7.81 | ||||
| Readmission Rate at DRG | 14.18 | ||||
| Readmission Rate with ICD T375X5A - Adverse effect of antiviral drugs, initial encounter | 27.45 | ||||
| Unplanned Readmission Rate at DRG | 9.63 | ||||
| Unplanned Readmission Rate with ICD T375X5A - Adverse effect of antiviral drugs, initial encounter | 12.75 | ||||
| Total Medicare payments at DRG | $111,849,779 | ||||
| Total Medicare payments with ICD T375X5A - Adverse effect of antiviral drugs, initial encounter | $873,702 | ||||
| Total Medicare payment per Day at DRG | $1,485 | ||||
| Total Medicare payment per Day with ICD T375X5A - Adverse effect of antiviral drugs, initial encounter | $1,087 | ||||
| Total Medicare payment per Hospitalization at DRG | $4,931 | ||||
| Total Medicare payment per Hospitalization with ICD T375X5A - Adverse effect of antiviral drugs, initial encounter | $8,483 | ||||
| Total Medicare Charges at DRG | $627,694,196 | ||||
| Total Medicare Charges with ICD T375X5A - Adverse effect of antiviral drugs, initial encounter | $6,425,309 | ||||
| Avg Charges at DRG | $27,675 | ||||
| Avg Charges with ICD T375X5A - Adverse effect of antiviral drugs, initial encounter | $62,382 | ||||
| Mortality Rate at DRG | 0.09 | ||||
| Mortality Rate with ICD T375X5A - Adverse effect of antiviral drugs, initial encounter | NA | ||||
| SNF Discharge Rate at DRG | 11.69 | ||||
| SNF Discharge Rate with ICD T375X5A - Adverse effect of antiviral drugs, initial encounter | NA | ||||
| Home Discharge Rate at DRG | 67.65 | ||||
| Home Discharge Rate with ICD T375X5A - Adverse effect of antiviral drugs, initial encounter | 59.22 |
*Readmission Rate is calculated from Oct 2015 to Aug 2018 and all other Quality Outcomes are calculated from Oct 2015 to Sep 2018.
| DRG 641: MISCELLANEOUS DISORDERS OF NUTRITION, METABOLISM , FLUIDS AND ELECTROLYTES WITHOUT MAJOR COMPLICATION OR COMORBIDITY (MCC) | DRG 070: NONSPECIFIC CEREBROVASCULAR DISORDERS WITH MAJOR COMPLICATION OR COMORBIDITY (MCC) | DRG 291: HEART FAILURE AND SHOCK WITH MAJOR COMPLICATION OR COMORBIDITY (MCC) | DRG 640: MISCELLANEOUS DISORDERS OF NUTRITION, METABOLISM , FLUIDS AND ELECTROLYTES WITH MAJOR COMPLICATION OR COMORBIDITY (MCC) | DRG 073: CRANIAL AND PERIPHERAL NERVE DISORDERS WITH MAJOR COMPLICATION OR COMORBIDITY (MCC) | |
|---|---|---|---|---|---|
| Total Hospitalizations at DRG | 310,318 | ||||
| Total Hospitalizations with ICD T375X5A - Adverse effect of antiviral drugs, initial encounter | 77 | ||||
| DRG Share of Total Hospitalizations | 0.94 | ||||
| % of Total ICD T375X5A - Adverse effect of antiviral drugs, initial encounter in DRG | 1.25 | ||||
| Avg LOS at DRG | 3.19 | ||||
| Avg LOS with ICD T375X5A - Adverse effect of antiviral drugs, initial encounter | 3.27 | ||||
| Readmission Rate at DRG | 20.19 | ||||
| Readmission Rate with ICD T375X5A - Adverse effect of antiviral drugs, initial encounter | 18.06 | ||||
| Unplanned Readmission Rate at DRG | 13.62 | ||||
| Unplanned Readmission Rate with ICD T375X5A - Adverse effect of antiviral drugs, initial encounter | NA | ||||
| Total Medicare payments at DRG | $1,415,392,709 | ||||
| Total Medicare payments with ICD T375X5A - Adverse effect of antiviral drugs, initial encounter | $378,318 | ||||
| Total Medicare payment per Day at DRG | $1,431 | ||||
| Total Medicare payment per Day with ICD T375X5A - Adverse effect of antiviral drugs, initial encounter | $1,501 | ||||
| Total Medicare payment per Hospitalization at DRG | $4,561 | ||||
| Total Medicare payment per Hospitalization with ICD T375X5A - Adverse effect of antiviral drugs, initial encounter | $4,913 | ||||
| Total Medicare Charges at DRG | $7,113,640,596 | ||||
| Total Medicare Charges with ICD T375X5A - Adverse effect of antiviral drugs, initial encounter | $1,930,822 | ||||
| Avg Charges at DRG | $22,924 | ||||
| Avg Charges with ICD T375X5A - Adverse effect of antiviral drugs, initial encounter | $25,076 | ||||
| Mortality Rate at DRG | 0.63 | ||||
| Mortality Rate with ICD T375X5A - Adverse effect of antiviral drugs, initial encounter | NA | ||||
| SNF Discharge Rate at DRG | 19.76 | ||||
| SNF Discharge Rate with ICD T375X5A - Adverse effect of antiviral drugs, initial encounter | NA | ||||
| Home Discharge Rate at DRG | 50.47 | ||||
| Home Discharge Rate with ICD T375X5A - Adverse effect of antiviral drugs, initial encounter | 59.74 |
| Hospital Name | Address | City | State | Zip Code | Total Hospitalizations ( Oct 2015 to Sep 2018 ) |
|---|---|---|---|---|---|
| UW HEALTH UNIVERSITY HOSPITAL | 600 HIGHLAND AVE | MADISON | WI | 53792 | 42 |
| EMORY UNIVERSITY HOSPITAL | 1364 CLIFTON RD NE | ATLANTA | GA | 30322 | 40 |
| UNIVERSITY OF MINNESOTA MEDICAL CENTER | 2450 RIVERSIDE AVE | MINNEAPOLIS | MN | 55454 | 38 |